BI-1607 is a humanized monoclonal antibody targeting CD32b/FcgammaRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcgammaRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907)[1].
Target-Kategorie:
Fc Receptor (FcR)
Anwendungsbeschreibung:
Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
